Significance of mitochondria on cardiometabolic syndromes. Fundam Clin Pharmacol 2018 Aug;32(4):346-356
Date
02/18/2018Pubmed ID
29453877DOI
10.1111/fcp.12359Scopus ID
2-s2.0-85046267771 (requires institutional sign-in at Scopus site) 12 CitationsAbstract
Metabolic syndromes (MS) are a cluster of disorders such as obesity, hypertension, dyslipidemia, and diabetes. Cardiometabolic syndrome (CMS), a branch of MS, is a group of diseases affecting cardiovascular, renal, metabolic, prothrombotic, and inflammatory abnormalities due to defects in energy metabolism. Since the emergence of molecular biology and the discovery of pathogenic mitochondrial DNA defect in the 1980s, research advances have revealed a number of common human diseases involving mitochondrial dysfunction. One of the major defects in CMS and its associated diseases is excess cellular oxidative stress and oxidative damage to mitochondrial components. In this study, we overview specific aspects of mitochondrial biology that have contributed and likely will continue enhance the progress of development of therapeutics for CMS. During the last decade, however, increasing evidence has emerged supporting the role of mitochondrial functional parameters in the genesis of various metabolism-related disorders. The biochemical pathways which modulate various mitochondrial functional indicators such as mitochondrial biogenesis, mitochondrial membrane potential, electron transport chain and ATP synthesis, intramitochondrial oxidative stress, and mitochondria-mediated cell death have been recognized in diagnosis and prognosis of various disorders associated with energy metabolism and heart function.
Author List
Anupama N, Sindhu G, Raghu KGAuthor
Anupama Nair Postdoctoral Researcher 3 in the Obstetrics and Gynecology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AnimalsHumans
Metabolic Syndrome
Mitochondria
Mitochondrial Diseases
Syndrome
